OGT to Share Strategies for Reliable NGS Panel Assays
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will share its expertise in NGS assay design by hosting a live webinar entitled ‘Enhanced bait design strategies that deliver more reliable NGS panel assays’ on 3 October 2013, at 3:00pm (BST).
Guest speaker, Dr Chris Mattocks, Senior Clinical Research Scientist at the National Genetics Reference Laboratory (Wessex), Salisbury UK, will discuss the advantages of hybridisation enrichment and the importance of optimal bait design to ensure increased uniformity for all target regions.
As the use of NGS moves closer to the clinic, it is of paramount importance that relevant mutations can be detected and called with complete certainty. Only reliable and reproducible methods will inspire enough confidence to allow the transition of NGS assays from useful research tools to clinically dependable tests.
As such, it is becoming increasingly apparent that some NGS enrichment methods do not reliably detect known mutants due to issues with PCR artefacts, excessive off-target enrichment, target region bias, non-uniformity of coverage or even wholesale target region drop-out. This highlights the need for methods with increased uniformity of coverage (when each locus is read at sufficient depth without resorting to increasing the number of reads) and minimal variation between loci, to provide confidence that all loci are covered at dependable levels.
As well as discussing bait design, the webinar will also cover the impact of coverage, non-conformity on sequencing efficiency and cost, and how coverage affects confidence levels in the results.
OGT’s significant expertise in NGS is demonstrated by Genefficiency Custom Targeted Sequencing Services, which combine expert bait design with a unique and fully interactive variant analysis report that delivers rapid access to reliable, meaningful results.
To register for the webinar, please visit the sign-up page.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance